Pleural lavage cytology predicts recurrence and survival, even in early non-small cell lung cancer

Federico Mazza, Enrico Ferrari, Paola Maineri, Beatrice Dozin, Giovanni Battista Ratto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Results: The PLC was positive in 15 patients (3.6 %). The overall five-year survival was 35.9 % in PLC-positive and 57.8 % in PLC-negative patients (p = 0.004). To compare groups with the same prognostic characteristics, the analysis was restricted to p-stage I patients, but the survival remained worse in the PLC-positive patients (42.9 vs 69.4 %; p = 0.001). Recurrence was also observed more frequently in PLC-positive cases: 69.2 vs 34.5 %, OR 4.28 (95 % CI 1.29–14.18; p = 0.01). Among the PLC-positive patients, no difference between the local (44.4 %) and distant (55.6 %) relapse patterns was found (p = 0.82). The multivariate analysis identified four independent prognostic factors: age (p 

Purpose: The TNM staging remains the best prognostic descriptor of lung cancer; however, new independent prognostic factors are needed, particularly for early stage disease.

Methods: An evaluation of the pleural lavage cytology (PLC) was performed in 436 consecutive NSCLC patients who underwent surgical resection; clinical, pathological and follow-up data were available for 414 patients.

Conclusions: PLC is an independent prognostic factor for NSCLC. PLC-positive NSCLC patients have a worse overall survival and a higher recurrence rate, even in stage I disease. PLC-positive patients should be considered a high risk category, who should potentially be eligible for adjuvant therapy regardless of their p-stage.

Original languageEnglish
Pages (from-to)322-328
Number of pages7
JournalSurgery Today
Volume45
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Therapeutic Irrigation
Non-Small Cell Lung Carcinoma
Cell Biology
Recurrence
Survival
Neoplasm Staging
Lung Neoplasms
Multivariate Analysis

Keywords

  • Cytology
  • Lung cancer
  • Lung resection
  • Prognosis
  • Staging

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Pleural lavage cytology predicts recurrence and survival, even in early non-small cell lung cancer. / Mazza, Federico; Ferrari, Enrico; Maineri, Paola; Dozin, Beatrice; Ratto, Giovanni Battista.

In: Surgery Today, Vol. 45, No. 3, 2014, p. 322-328.

Research output: Contribution to journalArticle

Mazza, Federico ; Ferrari, Enrico ; Maineri, Paola ; Dozin, Beatrice ; Ratto, Giovanni Battista. / Pleural lavage cytology predicts recurrence and survival, even in early non-small cell lung cancer. In: Surgery Today. 2014 ; Vol. 45, No. 3. pp. 322-328.
@article{16790c0caa644350bf750848aa71d337,
title = "Pleural lavage cytology predicts recurrence and survival, even in early non-small cell lung cancer",
abstract = "Results: The PLC was positive in 15 patients (3.6 {\%}). The overall five-year survival was 35.9 {\%} in PLC-positive and 57.8 {\%} in PLC-negative patients (p = 0.004). To compare groups with the same prognostic characteristics, the analysis was restricted to p-stage I patients, but the survival remained worse in the PLC-positive patients (42.9 vs 69.4 {\%}; p = 0.001). Recurrence was also observed more frequently in PLC-positive cases: 69.2 vs 34.5 {\%}, OR 4.28 (95 {\%} CI 1.29–14.18; p = 0.01). Among the PLC-positive patients, no difference between the local (44.4 {\%}) and distant (55.6 {\%}) relapse patterns was found (p = 0.82). The multivariate analysis identified four independent prognostic factors: age (p Purpose: The TNM staging remains the best prognostic descriptor of lung cancer; however, new independent prognostic factors are needed, particularly for early stage disease.Methods: An evaluation of the pleural lavage cytology (PLC) was performed in 436 consecutive NSCLC patients who underwent surgical resection; clinical, pathological and follow-up data were available for 414 patients.Conclusions: PLC is an independent prognostic factor for NSCLC. PLC-positive NSCLC patients have a worse overall survival and a higher recurrence rate, even in stage I disease. PLC-positive patients should be considered a high risk category, who should potentially be eligible for adjuvant therapy regardless of their p-stage.",
keywords = "Cytology, Lung cancer, Lung resection, Prognosis, Staging",
author = "Federico Mazza and Enrico Ferrari and Paola Maineri and Beatrice Dozin and Ratto, {Giovanni Battista}",
year = "2014",
doi = "10.1007/s00595-014-0915-3",
language = "English",
volume = "45",
pages = "322--328",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Pleural lavage cytology predicts recurrence and survival, even in early non-small cell lung cancer

AU - Mazza, Federico

AU - Ferrari, Enrico

AU - Maineri, Paola

AU - Dozin, Beatrice

AU - Ratto, Giovanni Battista

PY - 2014

Y1 - 2014

N2 - Results: The PLC was positive in 15 patients (3.6 %). The overall five-year survival was 35.9 % in PLC-positive and 57.8 % in PLC-negative patients (p = 0.004). To compare groups with the same prognostic characteristics, the analysis was restricted to p-stage I patients, but the survival remained worse in the PLC-positive patients (42.9 vs 69.4 %; p = 0.001). Recurrence was also observed more frequently in PLC-positive cases: 69.2 vs 34.5 %, OR 4.28 (95 % CI 1.29–14.18; p = 0.01). Among the PLC-positive patients, no difference between the local (44.4 %) and distant (55.6 %) relapse patterns was found (p = 0.82). The multivariate analysis identified four independent prognostic factors: age (p Purpose: The TNM staging remains the best prognostic descriptor of lung cancer; however, new independent prognostic factors are needed, particularly for early stage disease.Methods: An evaluation of the pleural lavage cytology (PLC) was performed in 436 consecutive NSCLC patients who underwent surgical resection; clinical, pathological and follow-up data were available for 414 patients.Conclusions: PLC is an independent prognostic factor for NSCLC. PLC-positive NSCLC patients have a worse overall survival and a higher recurrence rate, even in stage I disease. PLC-positive patients should be considered a high risk category, who should potentially be eligible for adjuvant therapy regardless of their p-stage.

AB - Results: The PLC was positive in 15 patients (3.6 %). The overall five-year survival was 35.9 % in PLC-positive and 57.8 % in PLC-negative patients (p = 0.004). To compare groups with the same prognostic characteristics, the analysis was restricted to p-stage I patients, but the survival remained worse in the PLC-positive patients (42.9 vs 69.4 %; p = 0.001). Recurrence was also observed more frequently in PLC-positive cases: 69.2 vs 34.5 %, OR 4.28 (95 % CI 1.29–14.18; p = 0.01). Among the PLC-positive patients, no difference between the local (44.4 %) and distant (55.6 %) relapse patterns was found (p = 0.82). The multivariate analysis identified four independent prognostic factors: age (p Purpose: The TNM staging remains the best prognostic descriptor of lung cancer; however, new independent prognostic factors are needed, particularly for early stage disease.Methods: An evaluation of the pleural lavage cytology (PLC) was performed in 436 consecutive NSCLC patients who underwent surgical resection; clinical, pathological and follow-up data were available for 414 patients.Conclusions: PLC is an independent prognostic factor for NSCLC. PLC-positive NSCLC patients have a worse overall survival and a higher recurrence rate, even in stage I disease. PLC-positive patients should be considered a high risk category, who should potentially be eligible for adjuvant therapy regardless of their p-stage.

KW - Cytology

KW - Lung cancer

KW - Lung resection

KW - Prognosis

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=84933052380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933052380&partnerID=8YFLogxK

U2 - 10.1007/s00595-014-0915-3

DO - 10.1007/s00595-014-0915-3

M3 - Article

C2 - 24817060

AN - SCOPUS:84933052380

VL - 45

SP - 322

EP - 328

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 3

ER -